Drugs / NV-5138
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05152680 | Nov → Dec 2021 | — | Navitor Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05384977 | Nov → Dec 2021 | — | Supernus Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03606395 | Jun 2018 → Jun 2019 | — | Navitor Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT06235905 | Feb → Aug 2024 | major depressive disorder | Navitor Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT05066672 | Jan 2022 → Jan 2025 | — | Navitor Pharmaceuticals, Inc. | Completed | Missed primary |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-04-21 | Supernus Pharmaceuticals, Inc. | Supernus and Navitor Announce Development and Option Agreement for Orally Active mTORC1 Activator NV-5138 supernus.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NV-5138 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03606395 ↗ |
| Known as | mefluleucine | “assessing rapid-acting effects of NV-5138 (mefluleucine), an intracellular enhancer of mechanistic target of rapamycin 1 synaptic signaling, for treatment-resistant depression.” PMID 41512716 ↗ Jan 2026 |
| Action | Activate | “an intracellular enhancer of mechanistic target of rapamycin 1 synaptic signaling” PMID 41512716 ↗ Jan 2026 |
| Modality | Small molecule | — CHEMBL4650303 ↗ |
| Route | Oral | “administered as an oral solution” NCT03606395 ↗ |